Evidence map›Paper›PMID 38328499›Full record

ArticleOpen forum infectious diseases2024

Stem Cell Transplant in Immune-deficiency-associated Vaccine-derived Poliovirus.

Heena Ranchod, Wayne Howard, Adele Roux, Walda van Zyl, Pieter Ekermans, Sylvia van den Berg, Lerato Seakamela, Koketso Makua, Mukhlid Yousif, Rosinah Sibiya and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Heena RanchodCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-6889-8126
Wayne HowardCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Adele RouxDr Adéle Roux Practice, Life Groenkloof Hospital, Pretoria, South Africa.
Walda van ZylDepartment of Medical Virology, Faculty of Health Sciences, University of Pretoria, National Health Laboratory Services-Tshwane Academic Division, Pretoria, South Africa.
Pieter EkermansDepartment of Medical Microbiology, Ampath Laboratories, Pretoria, South Africa.
Sylvia van den BergDepartment of Immunology, Ampath Laboratories, Pretoria, South Africa.
Lerato SeakamelaCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Koketso MakuaCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Mukhlid YousifCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Rosinah SibiyaCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Heleen Du PlessisCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Emmanuel PhalaneCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Kerrigan McCarthyCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Shelina MoonsamyCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
David ReyndersDepartment of Paediatrics, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Jeffrey HincksViroDefense, Chevy Chase, Maryland, USA.
Melinda S SuchardCentre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa.
Nicolette M du PlessisDepartment of Paediatrics, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with severe primary immunodeficiency are at risk for complications from live-attenuated vaccines. Here, we report a case of a vaccine-associated paralytic polio and Bacille Calmette-Guérin disease in a 6-month-old girl with severe combined immunodeficiency resulting from homozygous recombinant activating gene 1 deficiency. The patient was successfully treated with intravenous immunoglobulins and oral pocapavir for poliovirus, and antimycobacterial therapy for regional Bacille Calmette-Guérin disease, allowing stem cell transplant. Following transplantation, poliovirus type 3 with 13 mutations was detected from cerebrospinal fluid but not from stool, indicating ongoing viral evolution in the central nervous system despite pocapavir treatment. Clinical improvement and immune reconstitution allowed the patient to be successfully discharged with no further detection of poliovirus.

Indexed as

acute flaccid paralysisdisseminated BCGimmunodeficiencyintravenous immune globulinIRISiVDPVpocapavirpoliopoliomyelitisRAGSCIDstem cell transplanttransplantvaccine-associatedvaccine-derived poliovirusVAPP

Identifiers

PMID38328499
PMCPMC10849832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.